Welcome to our dedicated page for Quanterix news (Ticker: QTRX), a resource for investors and traders seeking the latest updates and insights on Quanterix stock.
Quanterix Corporation (QTRX) is a leader in ultra-sensitive digital immunoassay technology, enabling groundbreaking advancements in precision diagnostics and life sciences research. This dedicated news hub provides investors and industry professionals with comprehensive updates on the company's scientific developments and strategic initiatives.
Access timely, verified information about Quanterix's product innovations, research collaborations, and financial performance. Our curated collection includes earnings announcements, technology milestones, regulatory updates, and strategic partnerships that demonstrate the company's impact on biomarker detection capabilities.
Stay informed about QTRX's progress in commercializing its Simoa platform and expanding applications in neurological disorders, oncology, and infectious disease research. All content is meticulously organized to help stakeholders track the company's role in advancing next-generation diagnostic solutions.
Bookmark this page for direct access to official Quanterix communications and third-party analyses. Regularly updated with material developments, this resource supports informed decision-making about one of healthcare's most innovative diagnostic technology providers.
The FDA's recent approval of tofersen for treating SOD1-ALS marks a significant milestone, supported by compelling blood-based neurofilament light chain (NfL) measurements. This is the first instance of a blood biomarker being utilized as a surrogate endpoint for accelerated drug approval in neurology. Tofersen, which reduces the overproduction of SOD1 protein, demonstrated trends toward clinical benefit despite not significantly slowing disease progression in Phase III trials. The approach of using NfL measurements opens new avenues for neurodegenerative disease research and treatment, potentially impacting various conditions like Alzheimer's and multiple sclerosis. Quanterix Corporation, the developer of the Simoa NfL assay, plays a crucial role in this breakthrough, advancing biomarker use in clinical management.
Quanterix Corporation (NASDAQ: QTRX), a leader in biomarker detection, has announced that CEO Masoud Toloue will present at the Barclays Global Healthcare Conference on March 15, 2023, at 4:35 p.m. EDT. The company will also conduct one-on-one meetings with institutional investors on the same day. Investors can register for a virtual presentation via the provided link. Following the conference, the presentation and webcast will be accessible on Quanterix’s website. Quanterix is recognized for its Simoa® technology, which revolutionizes biomarker detection and supports significant research across various diseases.
Quanterix Corporation (NASDAQ: QTRX) announced its financial results for Q4 and the full year ended December 31, 2022. The company reported a Q4 GAAP revenue of $25.8 million, a 14.7% decline from the previous year, while full-year revenue was $105.5 million, down from $110.6 million in 2021. The gross margin for Q4 was 48.8%, improved from 41.1% in Q3 2022. The company reported an operating loss of $22.3 million, influenced by $10 million in restructuring costs. Despite the setbacks, the CEO noted progress in their strategic business realignment and promising advancements in Alzheimer's diagnostics.
Quanterix Corporation (NASDAQ: QTRX) announced that its CEO, Masoud Toloue, will present at Cowen’s 43rd Annual Health Care Conference on March 7, 2023, at 9:50 a.m. EST. The conference occurs from March 6-8, 2023, at the Boston Marriott Copley Place. Quanterix will host one-on-one meetings with institutional investors during the event. The presentation will be available via live audio webcast, and replays will be accessible afterward on the company's investor relations page. Quanterix specializes in ultrasensitive biomarker detection through its Simoa® technology, contributing to advancements in various fields including neurology and oncology.
FAQ
What is the current stock price of Quanterix (QTRX)?
What is the market cap of Quanterix (QTRX)?
